pulmonary large cell neuroendocrine carcinoma
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
NTRK2 positive AZD7451 pulmonary large cell neuroendocrine carcinoma sensitive detail...
NTRK1 dec exp NTRK2 dec exp AZD7451 pulmonary large cell neuroendocrine carcinoma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02279433 Phase I Taletrectinib A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Completed USA 0
NCT02687958 Phase II Everolimus Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin Unknown status ITA 0
NCT05470595 Phase II Atezolizumab A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung (LCNEC-ALPINE) Active, not recruiting DEU 0
NCT06613009 Phase I IBI3009 Study of IBI3009 in Subjects With Unresectable, Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Carcinomas Recruiting AUS 1
NCT06814496 Phase Ib/II Tarlatamab Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Recruiting USA 0
NCT06937905 Phase III Tarlatamab Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) (TARLANEC) Recruiting FRA 0
NCT07006727 Phase I 225Ac-ETN029 Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors Recruiting USA | CAN 1
NCT07707895 Phase Ib/II Atezolizumab + BI 764532 + Zocilurtatug pelitecan BI 764532 + Zocilurtatug pelitecan DAREON-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers Not yet recruiting USA | POL | NLD | GBR | FRA | ESP | DEU | BEL | AUS 2